BIOMARKER:

KEAP1 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

KEAP1 mutation	Non Small Cell Lung Cancer	KEAP1 mutation	Non Small Cell Lung Cancer	durvalumab + CP-675206 Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New B) durvalumab + CP-675206 Sensitive : B ESMO 2022 - 3wk	durvalumab + CP-675206 Sensitive: B - Late Trials ESMO 2022 - 3 weeks durvalumab + CP-675206 Sensitive : B ESMO 2022 - 3 weeks - (New B)
KEAP1 mutation	Non Small Cell Lung Cancer	KEAP1 mutation	Non Small Cell Lung Cancer	pembrolizumab + ramucirumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) pembrolizumab + ramucirumab Sensitive : C3 ESMO 2022 - 3wk	pembrolizumab + ramucirumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks pembrolizumab + ramucirumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KEAP1 mutation	Non Small Cell Lung Cancer	KEAP1 mutation	Non Small Cell Lung Cancer	DRP-104 Sensitive: B - Late Trials DRP-104 Sensitive : B	DRP-104 Sensitive: B - Late Trials DRP-104 Sensitive : B
KEAP1 mutation	Non Small Cell Lung Cancer	KEAP1 mutation	Non Small Cell Lung Cancer	durvalumab Resistant: B - Late Trials durvalumab Resistant : B	durvalumab Resistant: B - Late Trials durvalumab Resistant : B
KEAP1 mutation	Solid Tumor	KEAP1 mutation	Solid Tumor	IPN60090 Sensitive: C2 – Inclusion Criteria IPN60090 Sensitive : C2	IPN60090 Sensitive: C2 – Inclusion Criteria IPN60090 Sensitive : C2
KEAP1 mutation	Lung Non-Small Cell Squamous Cancer	KEAP1 mutation	Lung Non-Small Cell Squamous Cancer	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2
KEAP1 mutation	Non Small Cell Lung Cancer	KEAP1 mutation	Non Small Cell Lung Cancer	rivoceranib + camrelizumab Sensitive: C3 – Early Trials rivoceranib + camrelizumab Sensitive : C3	rivoceranib + camrelizumab Sensitive: C3 – Early Trials rivoceranib + camrelizumab Sensitive : C3
KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer	KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer	docetaxel Resistant: C3 – Early Trials docetaxel Resistant : C3	docetaxel Resistant: C3 – Early Trials docetaxel Resistant : C3
KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer	KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Resistant: C3 – Early Trials atezolizumab Resistant : C3	atezolizumab Resistant: C3 – Early Trials atezolizumab Resistant : C3
KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer	KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer	rivoceranib + camrelizumab Sensitive: C3 – Early Trials rivoceranib + camrelizumab Sensitive : C3	rivoceranib + camrelizumab Sensitive: C3 – Early Trials rivoceranib + camrelizumab Sensitive : C3
KEAP1 mutation	Non Small Cell Lung Cancer	KEAP1 mutation	Non Small Cell Lung Cancer	atezolizumab Resistant: C3 – Early Trials atezolizumab Resistant : C3	atezolizumab Resistant: C3 – Early Trials atezolizumab Resistant : C3
KEAP1 mutation	Non Small Cell Lung Cancer	KEAP1 mutation	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
KEAP1 mutation	Non Small Cell Lung Cancer	KEAP1 mutation	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
KEAP1 mutation	Lung Adenocarcinoma	KEAP1 mutation	Lung Adenocarcinoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
KEAP1 mutation	Lung Adenocarcinoma	KEAP1 mutation	Lung Adenocarcinoma	CB-228 + CB-839 Sensitive: C3 – Early Trials CB-228 + CB-839 Sensitive : C3	CB-228 + CB-839 Sensitive: C3 – Early Trials CB-228 + CB-839 Sensitive : C3
KEAP1 mutation	Lung Adenocarcinoma	KEAP1 mutation	Lung Adenocarcinoma	DRP-104 Sensitive: D – Preclinical DRP-104 Sensitive : D	DRP-104 Sensitive: D – Preclinical DRP-104 Sensitive : D
KEAP1 mutation	Lung Cancer	KEAP1 mutation	Lung Cancer	IPN60090 Sensitive: D – Preclinical IPN60090 Sensitive : D	IPN60090 Sensitive: D – Preclinical IPN60090 Sensitive : D